

BIOTECH Therapy



ERAPi

Technology matured by




Novel inhibitors of Endoplasmic-Reticulum Aminopeptidases (ERAPs) for the treatment of psoriasis and other autoimmune diseases.

- 1st ERAP2 selective inhibitors
- Several series of ERAP1 inhibitors

#Psoriasis

#Autoimmune disease

#MHC-I-opathies




Achievements :

- More than 100 analogues
- IC₅₀s from 200 nM to 4 nM
- ERAP2 potent selective inhibitors: KTGS chemistry
- Good ADME properties (on current ERAP2 lead)
- *In vivo* PoC on a psoriasis model
- ERAP-humanized animal created and available

IP status

PCT, Priority date : Dec. 18th 2020

EP, US, CA, CN, JP, IL



V. Camberlein et al. Ang. Chem. Int Ed. 2022 Sep 26;61(39):e202203560

CONTACT SATT Nord

Bruna GIOIA | Business Developer | bruna.gioia@sattnord.fr